Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10156MR)

This product GTTS-WQ10156MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10156MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1295MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ4358MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ7833MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ14963MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ2893MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ2564MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ2140MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ13200MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04950615
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW